These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 19583709

  • 1. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [Abstract] [Full Text] [Related]

  • 2. [Infliximab therapy for Crohn's disease anoperineal lesions].
    Ouraghi A, Nieuviarts S, Mougenel JL, Allez M, Barthet M, Carbonnel F, Cosnes J, Gendre JP, Flourié B, Meurisse JJ, Quandalle P, Ernst O, Lemann M, Cortot A, Modigliani R, Colombel JF.
    Gastroenterol Clin Biol; 2001 Nov; 25(11):949-56. PubMed ID: 11845044
    [Abstract] [Full Text] [Related]

  • 3. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 4. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L.
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [Abstract] [Full Text] [Related]

  • 6. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P.
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [Abstract] [Full Text] [Related]

  • 7. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG.
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [Abstract] [Full Text] [Related]

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 9. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 10. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 11. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar 01; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 12. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 13. Infliximab and surgical treatment of complex anal Crohn's disease.
    Duff S, Sagar PM, Rao M, Dolling S, Sprakes M, Hamlin PJ.
    Colorectal Dis; 2012 Aug 01; 14(8):972-6. PubMed ID: 21899707
    [Abstract] [Full Text] [Related]

  • 14. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
    Tanaka S, Matsuo K, Sasaki T, Nakano M, Sakai K, Beppu R, Yamashita Y, Maeda K, Aoyagi K.
    Hepatogastroenterology; 2010 Aug 01; 57(97):3-7. PubMed ID: 20422862
    [Abstract] [Full Text] [Related]

  • 15. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 16. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging.
    Karmiris K, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, Van Assche G.
    Clin Gastroenterol Hepatol; 2011 Feb 01; 9(2):130-6. PubMed ID: 21056696
    [Abstract] [Full Text] [Related]

  • 17. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 01; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

  • 18. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 19. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T, Göke B, Sackmann M.
    Am J Gastroenterol; 2002 Aug 01; 97(8):2022-5. PubMed ID: 12190171
    [Abstract] [Full Text] [Related]

  • 20. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.